A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis

Phase 4

• Conditions: Atopic dermatitis; eczema; 10014982

• Registration Number: NL-OMON53671
• Lead Sponsor: AbbVie B.V.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 14

Inclusion Criteria

- Male or female subjects >= 18 and < 65 years of age at the screening visit
- Chronic AD with onset of symptoms at least 3 years prior to Baseline and
subject meets Hanifin and Rajka criteria - Candidate for systemic treatment

Exclusion Criteria

- Prior exposure to any JAK inhibitor
- Unable or unwilling to discontinue current AD treatments prior to the study
- Requirement of prohibited medications during the study treatment
- Female subject who is pregnant, breastfeeding, or considering pregnancy
during the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoints are:<br /><br>- Achievement of EASI 90 at Week 24.</p><br>